文献速递生殖医学

一项关于胚胎植入前非整倍体遗传学检测的大型前瞻性非劣效性研究的实验设计局限使许多结论无效

Limits imposed by the experimental design of a large prospective non-inferiority study on PGT-A invalidate many of the conclusions.
PubMed 文献 · Hum Reprod · 2022-01-01

本文针对新英格兰医学杂志发表的一项14中心随机对照非劣效性试验提出方法学批评,该试验以累积活产率(CLBR)为终点比较常规体外受精与联合胚胎植入前非整倍体遗传学检测(PGT-A)的体外受精。作者指出该试验的胚胎仅按形态学选择后才随机分组并行PGT-A,使结局在研究干预前已确定,无法评估PGT-A对选择胚胎的潜在益处,且排除嵌合体胚胎等设计缺陷使非劣效结论不能成立,该研究数据实际表明PGT-A是安全的,但既不能支持也不能否定其临床有效性。

要点

  • 该试验在按形态学选定三枚胚胎后才随机分组并行PGT-A,结局在干预前已确定,无法评估PGT-A提高累积活产率的潜力。
  • 研究设计排除嵌合体胚胎移植,而文献显示这类胚胎具有显著生殖潜力,该决定缺乏证据基础。
  • 作者认为该研究数据实际表明PGT-A是安全的,但既不能支持也不能否定其临床有效性。

核心结论

  • 该试验的实验设计存在严重缺陷,其数据不支持原文发表的主要结论,即常规体外受精不劣于联合PGT-A的体外受精。
  • 作者认为该研究数据实际表明PGT-A干预是安全的,但该研究既不能支持也不能否定临床PGT-A的有效性。

研究设计与样本

  • 原文为针对新英格兰医学杂志发表的一项14中心随机对照非劣效性试验的方法学评论,该试验以累积活产率(CLBR)为临床终点比较常规体外受精与联合PGT-A的体外受精。

主要发现

  • 每例患者可移植的三枚胚胎池中的胚胎仅按形态学选择,随后患者被随机分配至PGT-A组或对照组,PGT-A筛查仅在胚胎被选择之后进行。
  • 由于随机化发生在胚胎选择之后,PGT-A组与对照组的累积结局在研究干预前已被决定,实验设计排除了评估主要终点的任何可能,该研究的主要问题从未被评估。
  • 研究设计排除嵌合体胚胎移植,而文献显示这些胚胎具有显著生殖潜力;计入这一非证据基础决定所导致的丢失活产后,两组的预期活产率变得几乎相同。
  • 研究者指出PGT-A组流产率较低但称其影响不足以改变CLBR;作者认为按设计CLBR被限定为等效,PGT-A组不存在改善结局的可能,因此较低的流产风险不可能提高CLBR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The New England Journal of Medicine recently published a large study addressing the efficacy of preimplantation genetic testing for aneuploidy (PGT-A). The 14-centre randomized control non-inferiority trial used cumulative live birth rate (CLBR) as a clinical endpoint to examine the value of PGT-A and concluded that conventional IVF was not inferior to IVF with PGT-A. Unfortunately, the experimental design was highly flawed; and in fact, the data generated in the study do not support the major conclusions presented in the publication. The embryos in each patient's three-embryo pool, which were available for transfer, were selected solely by morphology. The investigators then randomized patients to either the PGT-A group or the control group. It is important to note that PGT-A screening in the study group was done only after the embryos were selected. PGT-A was not really used in a meaningful way, which would have been for the PGT-A results to help in selecting which embryos would be in the three-embryo group. Thus, the outcomes were wholly determined prior to the study intervention. The ultimate delivery rate for each group of three embryos was determined when they were selected by morphology. The randomization, which occurred after embryo selection, would assure equal distribution of those cohorts destined to deliver and those destined to fail to the two study groups, the PGT-A and control groups. Thus, there was no potential for PGT-A to enhance selection and thus no possible way to improve the cumulative outcomes. Since there was no possible way for the control group to be inferior, the experimental design precluded any chance of evaluating the primary endpoint of the study. The primary question of the study was never evaluated. Another serious flaw was that the study was initiated prior to knowing how to interpret the data provided in the PGT-A analytical result. Specifically, the design excluded mosaic embryos from transfer despite the literature demonstrating the significant reproductive potential for these embryos. When accounting for the lost deliveries induced by this non-evidence-based decision, the expected delivery rates in the two groups become virtually identical. That is an important issue because the data from the study actually demonstrate the safety of PGT-A without diminution in outcomes from the impact of trophectoderm biopsy or the discarding of competent embryos which had wrongfully been considered aneuploid. A final serious flaw in the experimental design and interpretation of the data surrounding the issue of the miscarriage rate. The investigators noted that the miscarriage rate was lower in the PGT-A group but stated that its impact was insufficient to alter the CLBR. Of course, by design, the CLBRs were limited to being equivalent. There was no potential for enhanced outcomes in the PGT-A group and thus no possibility that the lower risk of miscarriage in the PGT-A group would raise the CLBR. The benefit of a lower miscarriage rate is real and significant. Its relevance should not be diminished based on the lack of a change in the CLBR since that was never possible in this study. The investigators of the study concluded that the CLBR with conventional ART is equivalent to that with PGT-A, but a simple review of the experiment reassigns their genuine findings to those of a safety study. Significantly, the data in the study demonstrate that the intervention of PGT-A is safe. This study neither supports nor refutes the efficacy of clinical PGT-A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Scott RT, de Ziegler D, Pirtea P, et al. Limits imposed by the experimental design of a large prospective non-inferiority study on PGT-A invalidate many of the conclusions. Hum Reprod. 2022. PMID: 36287636. doi:10.1093/humrep/deac224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。